Corbus Pharmaceuticals Holdings (CRBP) Research & Development (2013 - 2025)
Corbus Pharmaceuticals Holdings (CRBP) posted quarterly Research & Development of $20.9 million for Q3 2025, up 93.01% year-over-year from $10.8 million in Q3 2024, and up 37.35% quarter-over-quarter from $15.2 million in Q2 2025.
Corbus Pharmaceuticals Holdings (CRBP) Research & Development (2013 - 2025) Analysis & Trends
Corbus Pharmaceuticals Holdings' Research & Development history runs 13 years deep, the most recent figure standing at $20.9 million for Q3 2025.
- In Q3 2025, Research & Development rose 93.01% year-over-year to $20.9 million; the TTM figure through Sep 2025 stood at $60.5 million (up 98.84% YoY), while the FY2024 annual figure was $32.2 million, up 3.38% from the prior year.
- Research & Development for Q3 2025 stood at $20.9 million, up from $15.2 million in the prior quarter.
- The five-year high for Research & Development was $20.9 million in Q3 2025, with the low at $380000.0 in Q4 2021.
- The 5-year median for Research & Development is $7.0 million (2023), against an average of $8.5 million.
- The sharpest annual moves came in 2021 and 2022: Research & Development slumped 97.64% in 2021, then soared 1542.83% in 2022.
- Corbus Pharmaceuticals Holdings' Research & Development stood at $380000.0 in 2021, then jumped by 1542.83% to $6.2 million in 2022, then grew by 11.81% to $7.0 million in 2023, then gained by 25.89% to $8.8 million in 2024, then jumped by 137.4% to $20.9 million in 2025.
- Business Quant data shows CRBP's Research & Development at $20.9 million in Q3 2025, $15.2 million in Q2 2025, and $15.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | Corbus Pharmaceuticals Holdings | 121.72 Mn | -41.55 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 20.86 Mn |
| Jun 30, 2025 | 15.19 Mn |
| Mar 31, 2025 | 15.64 Mn |
| Dec 31, 2024 | 8.79 Mn |
| Sep 30, 2024 | 10.81 Mn |
| Jun 30, 2024 | 6.87 Mn |
| Mar 31, 2024 | 5.76 Mn |
| Dec 31, 2023 | 6.98 Mn |
| Sep 30, 2023 | 6.55 Mn |
| Jun 30, 2023 | 4.25 Mn |
| Mar 31, 2023 | 13.39 Mn |
| Dec 31, 2022 | 6.24 Mn |
| Sep 30, 2022 | 4.11 Mn |
| Jun 30, 2022 | 2.50 Mn |
| Mar 31, 2022 | 3.29 Mn |
| Dec 31, 2021 | 380,000.00 |
| Sep 30, 2021 | 8.70 Mn |
| Jun 30, 2021 | 11.27 Mn |
| Mar 31, 2021 | 10.72 Mn |
| Dec 31, 2020 | 16.11 Mn |